Interaction Color Code
Clinical Bottom Line
Do not coadminister: Reduced levels of dolutegravir
Drug 1
Drug 1 dose
50 mg once daily
Drug 1 effect
Cmax decreased 33%, AUC decreased 49%, Cmin decreased 73%
Drug 2
Drug 2 dose
300 mg BID
Drug 2 effect
Not studied
Clinical Effects
Potential decrease in antiretroviral efficacy
Management
Use alternative agents. If this combination must be used in an INSTI-na•ve adult patient, adminster dolutegravir 50 mg twice daily. Do not use in cases of clinically suspected InSTI resistance. Monitor antiviral efficacy
Alternative Agents
Gabapentin, Lamotrigine, Levitiracetam, Tiagabine, Topiramate
Import ID
124
